Exploring all things genetics. Dr Patrick Short, University of Cambridge alumnus and CEO of Sano Genetics, analyses the science, interviews the experts, and dis...
EP 175: Pioneering treatment for stop codon disease using tRNA with Michelle Werner of Alltrna
This week on The Genetics Podcast, Patrick is joined by Michelle Werner, CEO at Alltrna and CEO/Partner at Flagship Pioneering. They discuss Alltrna’s promising findings from its first preclinical study on using tRNA to rescue stop codon disease, the strategic use of basket trials, and more!Show Notes: 0:00 Intro to The Genetics Podcast01:00 Welcome to Michelle02:13 Overview of Alltrna’s aims and the advantages of using tRNA to tackle stop codon disease5:27 Using basket trials for genetic diseases08:03 Highlights from Alltrna’s first preclinical study using tRNA to restore protein production to clinically meaningful levels in methylmalonic acidemia (MMA) and phenylketonuria (PKU)14:02 Considerations in delivery techniques and Alltrna’s use of nanoparticles19:22 Stability of tRNA and how engineered tRNAs are recognized in vivo 23:12 Strategic design of basket trials and diseases that are covered26:16 Adaptive trial design in the rare genetic disease setting28:15 Michelle’s experience with regulatory organizations on new approaches to trial design32:14 Insights from spearheading Alltrna and Flagship Pioneering’s innovative approaches 37:26 Michelle’s lessons from working in big pharma versus a small biotech start-up40:50 Closing remarks and a call for collaboratorsFind out more Alltrna (https://www.alltrna.com/)Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link
--------
44:45
EP 174: Decentralized science and reducing the cost of gene therapies with Jocelynn Pearl of the TAM Center
On this week’s episode of The Genetics Podcast, we’re joined by Jocelynn Pearl, Director of Cancer Cell Therapy at the TAM Center, host of the Lady Scientist Podcast and Co-Founder of LabDAO. Patrick and Jocelynn discuss her move to Mexico to help accelerate the development of new cancer therapies, harnessing the power and potential of decentralized science, and overcoming sky-high gene therapy costs to increase accessibility for patients.Show Notes: 0:00Intro to The Genetics Podcast01:00Welcome to Jocelynn02:03 Jocelynn’s past work at The Institute for Systems Biology 04:55 How Jocelynn approached her transition to biotech from the world of academia10:14 Exploring decentralized science, including how it works and Jocelynn’s involvement to date15:54 What a Decentralized Autonomous Organisation (DAO) is and how this type of organizational structure supports scientific development22:45 The “fast grant” surge and other non-traditional funding methods28:00 Hosting the Lady Scientist Podcast and some of Jocelynn’s favorite moments32:43 Jocelynn’s move to Mexico to serve as Director of Cancer Cell Therapy at the TAM Center36:12 The biggest differences between building out drug development programs in Mexico and the US38:31 Regulatory differences between countries in the context of stem cell therapies42:48 The advantages for cancer therapeutic development in Jocelynn’s current environment46:20Driving down the costs of gene therapies and the impact on accessibility 48:09 Closing remarksFind out moreLabDAO:https://www.lab.bio/ Please considerrating and reviewing us on your chosen podcast listening platform!https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj
--------
46:08
EP 173: Tackling genetic cardiomyopathy from the bed to the bench with Eric Adler of Lexeo Therapeutics and UCSD
Summary:
This week on The Genetics Podcast, Patrick is joined by Eric Adler, Chief Medical Officer and Head of Research at Lexeo Therapeutics and Professor of Medicine at University of California San Diego. Eric shares his experience with genetic cardiomyopathy and his work on gene therapy for Danon disease, drawing from both clinical and research perspectives. Additionally, he explores the evolution of the field and the broader challenges faced by cardiovascular patients.
Show Notes:
0:00 Intro to The Genetics Podcast
01:00 Welcome to Eric and his efforts in cardiomyopathy at the bench and bedside
03:32 How modeling genetic diseases using pluripotent stem cells lead Eric to studying Danon disease
04:50 Pivoting from basic to translational research using adeno-associated viruses (AAV)-based gene therapy
07:58 Uncovering genetic cardiomyopathies that were misdiagnosed as idiopathic cardiomyopathy
09:55 Treatment, screening, and penetrance of Danon disease
12:30 Recent successes and remaining challenges in cardiovascular disease
19:47 Battling distrust in the medical profession
21:55 Preventative therapy using APOE2 for patients at risk of early Alzheimer’s
25:15 Motivations behind and advantages of Eric’s patient-centered approach to therapeutics
27:24 Balancing regulatory requirements for protocols versus patient needs
29:49 The importance of committed clinical partners for successful trial execution
36:08 Eric’s passion for cooking and how he won a cooking competition
39:02 Closing remarks and Lexeo Therapeutics’ aims for 2025
Find out more
Lexeo Therapeutics (https://www.lexeotx.com/)
Please consider rating and reviewing us on your chosen podcast listening platform!
https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link
--------
41:11
EP 172: Racial health disparities in genetic testing and breast cancer treatment with Dr. Versha Pleasant of University of Michigan
This week on The Genetics Podcast, Patrick is joined by Versha Pleasant, Clinical Assistant Professor in the Department of Obstetrics and Gynecology, University of Michigan and Director of the Cancer Genetics and Breast Health Clinic at Von Voigtlander Women’s Hospital. They discuss ongoing disparities in healthcare, in particular why black women in the US have a 40% higher chance of dying from breast cancer than white women, the impact of the US Educate Act on equality, diversity and inclusion education, and much more.
00:00:00 – Intro to The Genetics Podcast
00:01:52 – Welcome to Versha
00:03:22 – How black women have a 40% higher chance of mortality from breast cancer than white women, and the biggest drivers of this disparity
00:07:09 – Multifaceted approaches to addressing disparities
00:09:10 – Racial health duplicity and increasing access to genetic testing and mammography for black women
00:13:51 – The challenges of using precision medicine to stratify risk in black communities and historical harms in US medical research
00:14:29 – How to design for inclusive studies that effectively represent communities of colour
00:16:13 – Considering universal genetic testing and counseling for black women
00:21:24 – The logistics of making universal testing a reality, and the importance of community education and trust building
00:27:18 – What Versha is focused on next and the big topics she wants to tackle
00:33:24 – The role of community education and diversifying modes of communication for knowledge sharing
00:34:36 – Versha’s perspectives on the US Educate Act and the impact it could have on what doctors of the future are taught
00:40:52 – Versha’s advice to people who would like to pursue a similar career in medicine
00:43:28 – Where Patrick sees genetics evolving in the next ten years and his vision for the future of The Genetics Podcast
00:47:39 – Closing remarks
Find out more
Universal Genetic Counseling and Testing for Black Women: A Risk-Stratified Approach to Addressing Breast Cancer Disparities: https://www.clinical-breast-cancer.com/article/S1526-8209(24)00338-0/fulltext
Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link
--------
48:48
EP 171: The past, present, and future of long-read sequencing with Jonathon Hill of Wasatch Biolabs
This week on The Genetics Podcast, Patrick is joined by Jonathon Hill, associate professor at Brigham Young University and co-founder and VP of Wasatch Biolabs. Jonathan and Patrick discuss the power of long-read sequencing, how Wasatch Biolabs was created, and how Jonathon has fostered valuable collaborations between academic labs and Wasatch Biolabs.
Exploring all things genetics. Dr Patrick Short, University of Cambridge alumnus and CEO of Sano Genetics, analyses the science, interviews the experts, and discusses the latest findings and breakthroughs in genetic research. To find out more about Sano Genetics and its mission to accelerate the future of precision medicine visit: www.sanogenetics.com